Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tr1 cell–dependent active tolerance blunts the pathogenic effects of determinant spreading
Gizi Wildbaum, … , Nir Netzer, Nathan Karin
Gizi Wildbaum, … , Nir Netzer, Nathan Karin
Published September 1, 2002
Citation Information: J Clin Invest. 2002;110(5):701-710. https://doi.org/10.1172/JCI15176.
View: Text | PDF
Article Immunology

Tr1 cell–dependent active tolerance blunts the pathogenic effects of determinant spreading

  • Text
  • PDF
Abstract

Research Article

Authors

Gizi Wildbaum, Nir Netzer, Nathan Karin

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
(a–d) Groups of nine Lewis rats were immunized with MBPp87–99/CFA to ind...
(a–d) Groups of nine Lewis rats were immunized with MBPp87–99/CFA to induce active EAE. Just after the onset of disease (day 11) these rats were subjected to soluble peptide administration of MBPp87–99, MBPp68–86, PLPpAc224–240, or P2 (P2p57–81). Repeated administrations were given in a 12-hour interval during the subsequent 24 hours, and monitoring was done for clinical signs of disease (a). On day 11 following the first peptide administration, some of the groups that were subjected to soluble peptide therapy with MBPp87–99 (b) or MBPp68–86 (c) were also administered with neutralizing Ab’s to IL-4 or IL-10. (d) The kinetics of disease in rats that were administered with each of the above Ab’s without soluble peptide therapy. Mean EAE score ± SE of six rats per group is shown. Either normal rabbit IgG or affinity-purified polyclonal Ab’s from preimmunized rabbits were used as control Ab’s to anti–IL-4 and anti–IL-10. Their administration had no effect on the manifestation of disease, or on the suppressive effect of either soluble MBPp68–86 or MBPp87–99. (e) Levels of IL-10, IL-4, and IFN-γ obtained during the response to the spread determinant in spleen cells of rats that were subjected to active EAE induced by p87–99/CFA and subjected to soluble peptide therapy with various epitopes as described above. Spleen cells were obtained 24 hours after soluble peptide therapy was administered. Results are shown as mean of triplicates ± SE.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts